Overview

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Status:
Not yet recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS

Phase:

Phase 3

Details

Lead Sponsor:

Ahn-Gook Pharmaceuticals Co.,Ltd

Collaborator:

Daehwa Pharmaceutical Co., Ltd.